Chart Events
Performance Outlook
| Previous Close | 148.18 |
| Open | 149.92 |
| Bid | 151.21 x 800 |
| Ask | 151.31 x 800 |
| Day's Range | 150.26 - 153.76 |
| 52 Week Range | 115.03 - 217.25 |
| Volume | |
| Avg. Volume | 3,806,430 |
| Market Cap | 58.06B |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | 7.58 |
| EPS (TTM) | 19.87 |
| Earnings Date | May 02, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 226.64 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRNA
Related Research
- Moderna, Inc.Weekly Stock ListFor our list this week, we are focusing on the Healthcare Sector, which we rank as one of our favorites with an Over-Weight rating. Healthcare was an outperformer in 2022, falling only 4% while the S&P 500 dropped 19%, but has lagged in the early weeks of 2023. We think the recent relative weakness may offer a buying opportunity. Post-COVID, consumers are more willing to spend on lifestyle enhancements along with necessary spending on life-saving treatments. In addition, the survival of the Affordable Care Act has kept the ranks of insured U.S. citizens above the historical average, further increasing consumer spending on healthcare services and products. Meanwhile, companies with experience in diagnostic testing, vaccines, and antiviral medicines, as well as suppliers of protective equipment and other hospital products, have benefited from efforts to contain the pandemic. The sector accounts for 14.7% of the S&P 500, and includes companies in the pharmaceuticals, medical devices, healthcare services, and insurance industries. Here's our list of Argus BUY-rated Healthcare stocks that are large-cap and have solid books. We sorted by the largest percentage from the 52-week high.RatingFair ValueEconomic Moat24 days agoArgus Research
- Yahoo Finance Video
Moderna defends COVID-19 vaccine price hike before U.S. Senate
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss Moderna CEO Stephane Bancel’s testimony before the U.S. Senate health committee.
- Reuters
UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVID
Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio.
- ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co.
